| scholarly article | Q13442814 |
| P50 | author | Elisabeth Paietta | Q69071275 |
| Frederick R. Appelbaum | Q75025725 | ||
| Peter H. Wiernik | Q100309276 | ||
| P2093 | author name string | H M Lazarus | |
| J M Bennett | |||
| J M Rowe | |||
| K G Blume | |||
| P A Cassileth | |||
| D D Hurd | |||
| D P Harrington | |||
| D R Head | |||
| C Willman | |||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute myeloid leukemia | Q264118 |
| leukemia | Q29496 | ||
| chemotherapy | Q974135 | ||
| bone marrow | Q546523 | ||
| P304 | page(s) | 1649-56 | |
| P577 | publication date | 1998-12-03 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission | |
| P478 | volume | 339 |
| Q35849468 | 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. |
| Q44372696 | 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia |
| Q34295793 | A decade of progress in allogeneic hematopoietic cell transplantation: 1990-2000. |
| Q33610841 | A history of haemopoietic cell transplantation |
| Q52898922 | A modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia receiving allogeneic stem cell transplants. |
| Q34238046 | A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias |
| Q35628954 | A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia |
| Q24643266 | A phase 2 study of vorinostat in acute myeloid leukemia |
| Q46123564 | A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. |
| Q43181954 | A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study |
| Q43756723 | Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia |
| Q46353248 | Acute leukemia during pregnancy: a single institutional experience with 17 cases |
| Q34655572 | Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q36663603 | Acute myeloid leukaemia |
| Q34327218 | Acute myeloid leukaemia in adults |
| Q34677725 | Acute myeloid leukemia in adults |
| Q35008310 | Acute myeloid leukemia in children: a review of risk factors and recent trials |
| Q34334070 | Acute myeloid leukemia in the elderly: biology and therapeutic strategies. |
| Q34032840 | Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms |
| Q38644941 | Acute myeloid leukemia--major progress over four decades and glimpses into the future |
| Q34680933 | Acute myeloid leukemia: treatment of adults under 60 years |
| Q34680938 | Acute myeloid leukemia: treatment over 60. |
| Q37738546 | Acute myeloid leukemia: when to transplant in first complete remission |
| Q34062749 | Adoptive allogeneic immunotherapy--history and future perspectives |
| Q36593525 | Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group |
| Q34564663 | Age and acute myeloid leukemia |
| Q43791516 | Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy |
| Q53565869 | Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia. |
| Q47135533 | Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India |
| Q73398050 | Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality |
| Q38207595 | Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions |
| Q81778162 | Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question |
| Q35547257 | Allogeneic immune replacement as cancer immunotherapy |
| Q37842488 | Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations |
| Q26996818 | Allogeneic stem cell transplantation in first complete remission |
| Q43998105 | Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia. |
| Q43197991 | Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study |
| Q33202271 | Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: Onset versus relapse expression |
| Q35609792 | Antibody-based treatment of acute myeloid leukaemia |
| Q46981177 | Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants? |
| Q44440141 | Autologous Peripheral Blood Stem Cell Transplantation in First Remission Adult Acute Myeloid Leukaemia--An Intention to Treat Analysis and Comparison of Outcome Using a Predictive Model Based on the MRC AML10 Cohort |
| Q38090612 | Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia |
| Q33769677 | Autologous bone marrow transplantation in acute leukemia |
| Q44024539 | Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience |
| Q46600670 | Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy |
| Q50919144 | Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission. |
| Q79333289 | Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution |
| Q35122189 | Autologous stem cell transplantation for acute myeloid leukemia |
| Q38568355 | Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects |
| Q88887677 | Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the |
| Q35916382 | Autologous stem cell transplantation in hematological malignancies |
| Q36255287 | Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia |
| Q49286713 | Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission |
| Q40570930 | Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr. |
| Q35029920 | Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin |
| Q73650079 | Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome |
| Q45007020 | Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research |
| Q43267402 | BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. |
| Q49044408 | Baseline information in structural failure time estimators for the effect of observed treatment compliance. |
| Q74249650 | Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation |
| Q36850764 | Blood and marrow transplantation in elderly acute myeloid leukaemia patients - older certainly is not better |
| Q43620552 | Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC). |
| Q41928869 | Characteristics of De Novo Acute Myeloid Leukemia Patients in Palestine: Experience of An-Najah National University Hospital |
| Q33383210 | Characterization of hemopoietic engraftment kinetics and development of secondary cytopenia in AML post auto-SCT and its correlation with survival outcome. |
| Q37738440 | Chemotherapy for patients with acute myeloid leukemia in first remission |
| Q38031146 | Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group |
| Q35009273 | Clofarabine for the treatment of adult acute myeloid leukemia |
| Q36407434 | Cloretazine for the treatment of acute myeloid leukemia |
| Q40064058 | Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR. |
| Q44375011 | Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia |
| Q34630588 | Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission |
| Q79901810 | Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine |
| Q40487519 | Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy |
| Q34760577 | Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view |
| Q50778042 | Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan. |
| Q42538576 | Cyclophosphamide combined with mitoxantrone and cytarabine is an effective salvage regimen for patients with acute myeloid leukemia who experienced primary induction failure or relapse |
| Q80243112 | De novo acute myeloid leukemia in adults younger than 60 years of age: socioeconomic aspects and treatment results in a Brazilian university center |
| Q38608903 | Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification |
| Q73737109 | Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation |
| Q43800537 | Effects of azoles on human acute myelogenous leukemia blasts and T lymphocytes derived from acute leukemia patients with chemotherapy-induced cytopenia |
| Q73469851 | Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells |
| Q35703480 | Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies |
| Q34555592 | Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis |
| Q35981530 | Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma |
| Q43832873 | Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. |
| Q37039628 | Exploiting signal transduction pathways in acute myelogenous leukemia |
| Q42381012 | Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. |
| Q53600019 | Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. |
| Q43653729 | Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia |
| Q34747215 | Focus on acute leukemias |
| Q35848938 | Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction |
| Q37334588 | Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). |
| Q36630107 | Guidelines on the management of acute myeloid leukaemia in adults |
| Q34572795 | HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. |
| Q36865630 | HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. |
| Q34034180 | Hematopoietic stem cell transplantation for leukemia |
| Q37061969 | Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. |
| Q34297698 | High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CR. |
| Q73305168 | High-dose chemotherapy and autologous stem cell rescue for acute myeloid leukemia remains a safe, effective, and valid option |
| Q34317679 | High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis |
| Q45215896 | High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia |
| Q43710372 | High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation |
| Q73093108 | High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia |
| Q33787480 | Idarubicin including regimens in acute myelogenous leukemia in elderly patients. |
| Q34926682 | Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods |
| Q30941745 | Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation |
| Q73600964 | Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes? |
| Q43662947 | Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution |
| Q80521873 | Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant |
| Q38232465 | Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years |
| Q40011579 | Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia |
| Q53623884 | Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission. |
| Q44269630 | Intensified daunorubicin in induction therapy and autologous peripheral blood stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute myeloid leukemia |
| Q45204147 | Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995). |
| Q37676299 | Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. |
| Q30658847 | Interpreting outcome data in hematological malignancies: a paradigm for clinical studies |
| Q30884173 | Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases. |
| Q33978951 | Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. |
| Q53298938 | Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis |
| Q36152695 | Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? |
| Q37693943 | Laromustine (cloretazine). |
| Q24653888 | Lifetime probabilities of hematopoietic stem cell transplantation in the U.S |
| Q54023930 | Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). |
| Q44849776 | Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia |
| Q44053983 | Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia |
| Q40567141 | Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission |
| Q45254762 | Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. |
| Q31030133 | Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia |
| Q73720132 | Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials |
| Q37023840 | Maintenance for acute myeloid leukemia revisited |
| Q35599067 | Management of acute myelogenous leukemia in the elderly |
| Q36121885 | Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT |
| Q44033088 | Mononucleosis syndrome and acute monocytic leukemia |
| Q34217884 | Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood |
| Q46729975 | Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients |
| Q42711146 | Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation |
| Q92623047 | Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia |
| Q35574536 | Myeloablative conditioning regimens for AML allografts: 30 years later |
| Q37418318 | New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. |
| Q80166478 | Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial |
| Q44287669 | Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission |
| Q94503157 | Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia |
| Q46447370 | One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission |
| Q38208953 | Optimal therapy for adult patients with acute myeloid leukemia in first complete remission |
| Q36075433 | Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation |
| Q46216906 | Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype |
| Q34038567 | Overview of autologous stem cell transplantation. |
| Q36246359 | Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. |
| Q35750919 | Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias |
| Q34320196 | Postremission therapy in adults with acute myeloid leukemia |
| Q34634662 | Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial |
| Q46600591 | Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. |
| Q44630730 | Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation |
| Q37603180 | Principles and overview of allogeneic hematopoietic stem cell transplantation. |
| Q37006786 | Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience |
| Q36599544 | Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). |
| Q27024006 | Progress in acute myeloid leukemia |
| Q36929806 | Progress in the treatment of acute myeloid leukemia |
| Q34720554 | Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker |
| Q34608650 | Radioimmunotherapy for acute leukemia |
| Q73540103 | Randomised studies in acute myeloid leukaemia: the double truth |
| Q84698071 | Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study |
| Q89673632 | Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia |
| Q79954889 | Reassessing autotransplantation for acute myeloid leukaemia in first remission - a matched pair analysis of autologous marrow vs peripheral blood stem cells |
| Q34383226 | Recent advances in the treatment of AML. |
| Q35152603 | Recent advances in the treatment of infant acute myeloid leukemia |
| Q82569111 | Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia |
| Q44471803 | Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. |
| Q43152085 | Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype |
| Q37942816 | Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia |
| Q37567632 | Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia |
| Q36152664 | Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia |
| Q37419348 | Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia |
| Q26771438 | Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia |
| Q44529446 | Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial |
| Q79172255 | Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis |
| Q34268110 | Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia |
| Q35030141 | Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia |
| Q47611845 | Should we T cell deplete sibling grafts for acute myeloid leukaemia in first remission? |
| Q46705877 | Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report |
| Q41902244 | Stem cells in hemato-oncology |
| Q53372929 | Survival-weighted health profile for long-term survivors of acute myelogenous leukemia. |
| Q39021231 | T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. |
| Q35236079 | T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis |
| Q47124626 | Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity |
| Q33944427 | Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia |
| Q37885167 | The EBMT risk score |
| Q37228646 | The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting |
| Q35903540 | The role of allogeneic transplantation in high-risk acute myelogenous leukemia |
| Q34355952 | The role of bone marrow transplantation in acute promyelocytic leukemia |
| Q44043143 | The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison |
| Q35610850 | The therapy of relapsed acute leukaemia in adults |
| Q36269943 | The treatment of AML: current status and novel approaches |
| Q34525604 | The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial |
| Q37271941 | Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years |
| Q34380840 | Therapeutic options for acute myelogenous leukemia |
| Q34108107 | Therapy for childhood acute myeloid leukemia: role of allogeneic bone marrow transplantation |
| Q44280535 | Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide |
| Q74677559 | Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune response |
| Q73916909 | Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission |
| Q46656673 | Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. |
| Q37486793 | Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation |
| Q36284532 | Treatment of childhood acute myeloid leukemia |
| Q38176519 | Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). |
| Q78842147 | Treatment options for patients with acute myeloid leukemia with a matched sibling donor: a decision analysis |
| Q35824988 | Unanswered questions in acute myeloid leukaemia |
| Q33841417 | Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission |
| Q34326698 | Unrelated donor hematopoietic transplantation |
| Q78550611 | Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies |
| Q41894404 | Update on optimal management of acute myeloid leukemia |
| Q37163399 | Use of biological assignment in hematopoietic stem cell transplantation clinical trials |
| Q34534299 | Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells |
| Q53474437 | Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. |
| Q89112359 | Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience |
| Q28190017 | Who should be transplanted for AML? |
| Q35077929 | Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients |
Search more.